High somatic copy number alterations in melanoma patients have recently been linked with less effective response to immune checkpoint blockade anti–CTLA-4 (cytotoxic T lymphocyte–associated protein 4) therapy [52]. The gene discussed is CTLA4; the disease is melanoma.